These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27009493)

  • 21. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells.
    Riegel C; Boeld TJ; Doser K; Huber E; Hoffmann P; Edinger M
    Leukemia; 2020 Mar; 34(3):895-908. PubMed ID: 31719679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.
    Zhao XS; Wang YN; Lv M; Kong Y; Luo HX; Ye XY; Wu Q; Zhao TF; Hu YH; Zhang HY; Huo MR; Wan J; Huang XJ
    Oncotarget; 2016 Jul; 7(30):48321-48334. PubMed ID: 27340781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ex vivo toll-like receptor 7 tolerance induction in donor lymphocytes prevents murine acute graft-versus-host disease.
    Zogas N; Karponi G; Iordanidis F; Malasidis S; Paraskevas V; Papadopoulou A; Scouras ZG; Anagnostopoulos A; Yannaki E
    Cytotherapy; 2018 Jan; 20(1):149-164. PubMed ID: 29150086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease
    Liu H; Yu Z; Tang B; Miao S; Qin C; Li Y; Liang Z; Shi Y; Zhang Y; Wang Q; Yan M; Song Z; Ren H; Dong Y
    Front Immunol; 2021; 12():647894. PubMed ID: 34262560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.
    Kim KW; Moon SJ; Park MJ; Kim BM; Kim EK; Lee SH; Lee EJ; Chung BH; Yang CW; Cho ML
    Stem Cell Res Ther; 2015 Oct; 6():202. PubMed ID: 26497134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L; Nusair S; Reich S; Sidi H; Slavin S
    Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Hildebrandt GC; Choi SW; Mueller G; Olkiewicz KM; Moore BB; Cooke KR
    Pediatr Blood Cancer; 2008 Apr; 50(4):911-4. PubMed ID: 17455319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease.
    Maeda Y; Tawara I; Teshima T; Liu C; Hashimoto D; Matsuoka K; Tanimoto M; Reddy P
    Exp Hematol; 2007 Feb; 35(2):274-86. PubMed ID: 17258076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant.
    Song N; Gao L; Qiu H; Huang C; Cheng H; Zhou H; Lv S; Chen L; Wang J
    Int J Mol Med; 2015 Jul; 36(1):139-49. PubMed ID: 25901937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
    Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T
    Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [α-GalCer reduces Acute Graft-versus-Host Disease by Altering Donor T Cells Migration].
    Liu JH; Zhou F; Liu Y; Zhang XL; Li MY; Liu YQ; Wang JG; Bai Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):843-7. PubMed ID: 26117047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased expression of interleukin-18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Fujimori Y; Yoshimoto T; Matsui K; Tsutsui H; Okamoto T; Kashiwamura S; Hada T; Okamura H; Kakishita E; Hara H; Nakanishi K
    J Interferon Cytokine Res; 2002 Jul; 22(7):751-4. PubMed ID: 12184912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.
    Lee SH; Moon SJ; Park MJ; Kim EK; Moon YM; Cho ML
    Immunol Lett; 2014 Jul; 160(1):79-88. PubMed ID: 24718277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
    Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.